In the modern business world, where doing things holistically is a Board directive, adopting an enterprise-wide approach to managing governance, risk and compliance (GRC) is a no-brainer. Unlike other business philosophies that have come and gone, this is no fad; it is a forward-thinking way of working that has taken root across industries. Unfortunately, organizations often struggle to implement GRC in an integrated and synchronized manner, aligned with business processes and strategic objectives – and it is easy to see why.

A quick check of the global pharmaceutical (pharma) industry’s temperature shows that it is in good health: worth approximately $934.8 billion in 2017, it is estimated to reach over $1,170 billion this year. This encouraging prognosis has been aided by several factors – from rising incomes and enhanced medical infrastructures to rapid advancements in the treatment of chronic diseases and the prevalence of patented products.

We hear a lot about the ‘risk landscape’: a turbulent place where change lurks around almost every corner and variables abound. This powerful metaphor brings to life the need for firms in the financial services sector to navigate through the risks and pitfalls between where they currently are as an enterprise, and where they should be. One event – the global financial crisis – reshaped the topography of the space by changing business conditions and regulatory requirements. Analysts now identify three distinct periods within the financial services risk landscape over the last two decades:

We are delighted to announce that Camms.Risk was once again named as a “High Performer” in the GRC Platform category of G2’s Spring 2021 Report. The accolade marks the 10th consecutive quarter that Camms.Risk has been recognised as a “High Performer” in this category.